Forge Biologics

☀️Live from San Diego! Our gene therapy experts are here at the Biotechnology Innovation Organization International Convention this week. Here’s how you can connect with Forge 👇 • Visit booth 5313 and take a VR tour of our facility • Join our company presentation today at 3:45 pm PST in theater 4 • Meet us at the Ohio Life Sciences Reception at booth 5707 today at 5 pm • Attend our reception with Ajinomoto Bio-Pharma Services, stop by our booth to learn more! View our full presence and book a meeting with our team here ➡️https://bit.ly/4bHtk7h

🧬 Starting with the end in mind Our commercially viable platform can support easier development, scale-up, reduce bridging studies, and minimize risks to future approvals. Learn more about utilizing our bespoke platform as a foundation for accelerated development ➡️ https://bit.ly/3X6yxki

Don't miss Forge at BIO next week! Our gene therapy experts will be in San Diego at booth 5313 to share the latest ways we bring life-changing discoveries from concept to reality. View our full presence and book a meeting with our AAV experts in San Diego here ➡️ https://hubs.li/Q02z6TpB0

“FBX-101 represents a promising and innovative approach to treat patients with Krabbe disease by targeting the underlying genetic cause of the disorder and potentially offering disease-modifying effects.” Dr. Maria L Escolar, MD, MS, shares progress on Forge’s AAV therapy for patients with Krabbe disease in an interview with the European Pharmaceutical Review Read the full interview here ➡️ https://hubs.li/Q02yZrS40

Our pEMBR™ Ad helper plasmid is used by more than 80% of our clients. Here’s why 👇 • Immediately available at research and phase I/II GMP-Pathway grades • Shows equivalent AAV yields as compared to commercially available alternatives • Improved safety profile, engineered to reduce known immunogenic elements • Decreased size increases efficiency in manufacturing Learn how you can accelerate your AAV program using our proprietary technologies at Forge ➡️ https://hubs.li/Q02yPT_q0

Uncover your cell lysis legend status at BIO! Our recently unveiled game will be available to play at the Biotechnology Innovation Organization International Convention in San Diego June 3-6. Put your gaming and AAV manufacturing skills to the test at booth #5313 where you can earn a spot on the AAV leaderboard. View our full presence and book a meeting with our AAV experts in San Diego here ➡️ https://hubs.li/Q02yFyKC0

Hear John Maslowski, Forge's Chief Commercial Officer, highlight top industry growth trends and how Forge enables access to genetic medicines through better manufacturing in his interview with IB Communications at ASGCT 2024! Watch the full interview here ➡️ https://hubs.li/Q02yfWSr0

"All of this could not be done without the families and [patient support] foundations that trust us with this important work." Hunter's Hope Foundation, KrabbeConnect, Rosenau Family Research Foundation   Forge's Chief Medical Officer, Maria L Escolar, MD, MS, was interviewed by Noah Stanfield from CGTLive about her late-breaking presentation at ASGCT 2024, where she provided a clinical update on REKLAIM, our Phase 1b clinical trial for patients with Krabbe Disease. Data from patients treated with Forge's novel gene therapy FBX-101 demonstrate continued safety and efficacy, and include improved gross-motor function, one of the most significant results for patients suffering from this debilitating and rapidly progressing disease.   Listen to the full interview here ➡️ https://lnkd.in/emn5VFjf

Exciting news! Our 4th annual intern class has been sequenced! These 15 gene-ius individuals selected from hundreds of applicants will be contributing to Forge's mission across 8 departments this summer. We cannot wait to further fuel their passion for science, manufacturing, and gene therapy development as they grow and advance in Forge's innovative summer program. Join us in giving a DNAmazing welcome to our latest Ignite Interns, and stay tuned for updates throughout the summer!

In the world of clinical research, the path forward is forged through the relentless pursuit of knowledge, adherence to best practices, and an unwavering commitment to championing patient well-being. On this Clinical Trials Day, we recognize the invaluable work of clinical research professionals and their dedication to advancing human health. Their commitment is what makes medical breakthroughs possible. At Forge, we rely on clinical trials like our REKLAIM Phase 1b clinical trial for patients with Krabbe disease, to ensure we deliver safe and efficacious therapies to our patients while also supporting our clients through the manufacturing of therapies for clinical trials and beyond. As we continue our own clinical trials and enable access to potentially life-changing medicines, we maintain a patient-first approach, with safety and consent as our paramount priorities.